The rationale for targeting L. iners rather than simply eliminating all bacteria rests on a growing body of ecological evidence. Vaginal communities are classified into five major community state types, with CST I dominated by L. crispatus and CST III dominated by L. iners. Although CST III also occurs in asymptomatic women, L. iners-dominated communities have been associated with greater Candida colonization, reduced clearance of high-risk human papillomavirus infection and, in specific cohorts, poorer in vitro fertilization outcomes. Reduced L. crispatus abundance, meanwhile, has been linked to spontaneous preterm birth. Because bacterial vaginosis recurrence remains common after metronidazole therapy and post-treatment communities frequently remain or become dominated by L. iners, the post-antibiotic interval represents a strategic window in which ecological steering toward L. crispatus dominance might be achievable.

The researchers began with metabolic profiling. Using API 50 CH carbohydrate strips across five strains of each Lactobacillus species, they found that L. crispatus displayed broader, strain-dependent carbohydrate utilization, while all five L. iners strains fermented only glucose and maltose and none utilized galactose, xylose or raffinose. This raised the possibility of prebiotic selectivity: substrates that L. crispatus could exploit but L. iners could not. However, when galactose, xylose and raffinose were tested in monocultures, all five L. iners strains reached comparable viable counts, meaning the carbohydrates provided insufficient selectivity to favour L. crispatus under the nutrient-rich conditions tested. The authors report this negative result candidly, noting that alternative excipients such as alginate, sucrose and trehalose, which have shown promise in other studies, warrant further comparative evaluation.

A striking incidental finding emerged from the culture work: when defibrinated horse blood was omitted from the growth medium, none of the five L. iners strains could replicate. This observation, consistent with the species’ known cysteine dependence and predicted heme-associated functions, suggested that L. iners relies on blood-derived nutrients, including heme-associated iron. The team therefore turned to nutritional restriction as a selective strategy, selecting Vitis vinifera-derived oligomeric proanthocyanidins (OPCs), which can sequester iron, amino acids and peptides, and ethylenediaminetetraacetic acid (EDTA), a metal chelator with established antibiofilm credentials. In simulated vaginal fluid supplemented with 3% boric acid, 0.25% OPCs, 0.05% EDTA and 0.5% raffinose, L. iners viability fell by approximately 3 log10 CFU/mL over 48 hours, while most L. crispatus strains were affected far less. Subsequent compatibility screening identified 0.25% OPCs plus 0.05% EDTA as the combination least inhibitory to L. crispatus.

The decisive selectivity, however, came from fatty acids. Testing oleic, linoleic and palmitoleic acids by broth microdilution, the researchers found that oleic acid offered the widest differential between the two lactobacilli. For L. iners DSM 13335, the minimum inhibitory and bactericidal concentrations were 0.4 and 0.8 mM respectively, whereas the corresponding endpoints for three L. crispatus strains ranged from 1.6 mM to beyond 6.4 mM, the highest concentration tested. Linoleic and palmitoleic acids inhibited both species within a narrower window. The mechanistic explanation, drawn from prior work, is elegant: L. crispatus possesses the oleate hydratase OhyA and a putative fatty-acid efflux protein, FarE, which together support fatty-acid utilization and tolerance, while L. iners lacks these functions. Oleic acid thus acts as an ecological selector rather than a blunt antimicrobial.

When the full three-component mixture of 0.25% OPCs, 0.05% EDTA and 6.4 mM oleic acid was challenged against vaginal microorganisms for 24 hours, the results were pronounced. L. iners counts fell by approximately 4.8 log10 CFU/mL relative to controls, while the three L. crispatus strains showed only 0.3 to 0.5 log10 CFU/mL reductions that were not statistically significant. All four clinically relevant Candida species tested, C. albicans, C. glabrata, C. krusei and C. parapsilosis, showed significant reductions of roughly 1.4 to 2.5 log10 CFU/mL, even though individual fatty acids alone had shown no fungicidal activity at the concentrations tested, suggesting that component interactions, antiadhesive effects or antibiofilm mechanisms may underlie the antifungal activity. Cytotoxicity testing in HeLa cells showed no significant increase in lactate dehydrogenase release at dilutions of 1.56 to 12.5% of the undiluted preparation, but significant, concentration-dependent membrane damage appeared at 25 to 100%, highlighting that an overlapping active and cytocompatible exposure window has yet to be established.

The second module of the study addressed direct fungal suppression through statin chemistry. Monacolin K is chemically identical to lovastatin, and its β-hydroxy acid form, monacolin KA, directly inhibits HMG-CoA reductase in the fungal mevalonate pathway, restricting ergosterol synthesis. In overnight assays, purified monacolin KA showed the broadest antifungal activity, reducing C. albicans counts by approximately 4.3 log10 CFU/mL at 50 µg/mL, with C. albicans and C. glabrata particularly responsive and C. krusei less susceptible, a pattern consistent with known species-dependent statin responses. Monacolin K showed a narrower spectrum, active against C. albicans, C. glabrata and C. parapsilosis. Critically, both compounds preserved high L. crispatus viability at the tested concentrations, with M247, SS and DC reaching counts of 8.34 to 8.88 log10 CFU/mL at 25 to 50 µg/mL. By testing purified compounds rather than complex red-yeast-rice preparations, the authors avoided confounding by other fermentation metabolites and identified monacolin KA as the priority antifungal candidate.

Translational support came from an exploratory longitudinal observation of a 32-year-old woman undergoing assisted reproductive treatment, reported under the CARE guidelines. Her vaginal microbiota initially showed a CST I profile with L. crispatus at roughly 95% relative abundance, but symptomatic bacterial vaginosis in April 2024 shifted the community to CST IV. After intravaginal and oral metronidazole, the profile became CST III, with L. iners accounting for 99.087% of the community. Following recurrent Gardnerella dominance, an intravaginal prototype containing 0.25% OPCs and 0.05% EDTA in an extra-virgin olive-oil vehicle was introduced alongside continued oral L. crispatus M247 supplementation and a short boric acid course. Over the following months, L. crispatus rose from 0.020% to 5.695%, then 25.341%, 68.338% and finally 96.862% by April 2026, at which point the community had returned to CST I, Gardnerella was undetectable, L. iners accounted for only 0.337% and the patient was asymptomatic. No treatment-related adverse events were reported.

The authors are careful to emphasize the limitations of this clinical signal. The prototype differed from the laboratory mixture containing free oleic acid, and the concomitant treatments preclude any attribution of the microbiota transition to the prototype alone. The evidence base remains predominantly in vitro, no animal studies were performed, and only a single clinical observation is available. Short-term monocultures cannot reproduce epithelial interactions, hormonal variation, multispecies biofilms, local retention or repeated exposure, and effects on the CST IV-associated bacteria that drive bacterial vaginosis require direct evaluation. Cytocompatibility also needs refinement, with further assessment planned in non-transformed vaginal epithelial cells or reconstructed vaginal tissue, including repeated exposures and measurements of barrier integrity.

Nevertheless, the study lays out a coherent blueprint for a new generation of intravaginal formulations that work with vaginal ecology rather than against it. The bacterial-selective module could serve as an adjunctive or post-antibiotic therapy for bacterial vaginosis, targeting the frequent emergence of L. iners during recovery, and the association between CST III and reduced HPV clearance provides a rationale for future studies of whether microbiota modulation affects viral persistence. The monacolin module targets settings where Candida colonization or recurrent vulvovaginal candidiasis predominates, a condition with a substantial global burden. Ongoing work is exploring a standardized, fractionated Pistacia lentiscus berry oil rich in oleic acid as a natural alternative to purified oleic acid, potentially extending activity to Streptococcus agalactiae, and reassessing boric acid inclusion. The next steps, standardized manufacture, stability studies, polymicrobial vaginal models and controlled clinical comparisons, will determine whether this laboratory selectivity can translate into sustained L. crispatus dominance in patients.

Subject of Research: Selective modulation of the vaginal microbiota to suppress Lactobacillus iners and Candida while preserving Lactobacillus crispatus

Article Title: Vaginal formulations selectively target Lactobacillus iners and Candida spp. while preserving Lactobacillus crispatus

Article References: Di Pierro, F., Sagheddu, V., Galletti, S., Casaroli, A., Soldi, S., Bertuccioli, A., Palazzi, C. M., Senatori, R., Carugno, A., Antipov, M. O., Briko, N. I., & Zerbinati, N. (2026). Vaginal formulations selectively target Lactobacillus iners and Candida spp. while preserving Lactobacillus crispatus. International Microbiology. https://doi.org/10.1007/s10123-026-00906-0

Image Credits: AI Generated

DOI: 10.1007/s10123-026-00906-0

Keywords: vaginal microbiota, Lactobacillus crispatus, Lactobacillus iners, Candida, oleic acid, oligomeric proanthocyanidins, EDTA, monacolin KA, bacterial vaginosis, community state types, probiotics, antifungal

The study, published online in the journal Microbiology Spectrum on August 21, 2026, was led by Professor Hiroki Takahashi of the Medical Mycology Research Center at Chiba University, with co-authors Dr. Isato Yoshioka, Dr. Momotaka Uchida, Professor Akira Watanabe, and Dr. Takashi Yaguchi. Their approach combines selective depletion of human DNA, whole-genome amplification, and real-time nanopore sequencing into a single streamlined pipeline designed to work on samples collected while the blood culture is still incubating. The result is species-level identification of fungal pathogens with remarkably high accuracy, achieved well before conventional systems would alert clinicians that anything is growing at all.

The clinical stakes are considerable. Candida species are responsible for the majority of invasive fungal infections worldwide and rank among the leading causes of hospital-acquired bloodstream infections overall. Because different fungal species respond differently to antifungal drugs—some are susceptible to first-line agents such as fluconazole, while others, like certain strains of Nakaseomyces glabratus, show reduced susceptibility—doctors strive to identify the specific organism before committing to a treatment regimen. In the absence of rapid identification, clinicians face an unenviable choice: start broad-spectrum antifungal therapy that may be unnecessary or suboptimal, or delay targeted treatment while the diagnostic clock ticks.

Conventional diagnosis compounds this dilemma. Blood cultures require incubation until microbial growth reaches levels that automated detection systems can register, a process that alone can take one to several days depending on the organism and the burden of infection. Only after the culture turns positive do laboratory staff perform identification tests to determine which species is present. During this entire window, the patient’s infection continues to progress. The Chiba University team set out to attack precisely this bottleneck by interrogating the sample before the culture system declares it positive.

The workflow unfolds in three main steps. First, the researchers selectively break down human cells in the blood culture sample and then degrade liberated human DNA using an enzyme called benzonase, which leaves fungal and bacterial DNA intact. This host-DNA depletion step is critical: in blood, human genetic material vastly outnumbers microbial DNA, and without removing it, fungal sequences would be buried under an avalanche of irrelevant signal. By stripping away the host background, the method dramatically increases the proportion of pathogen DNA available for analysis.

Next comes amplification. Because even a depleted sample contains only small quantities of pathogen DNA, the team employs PCR-based whole-genome amplification to make many copies of DNA fragments from across the genomes present in the sample. This random amplification strategy does not target specific genes; instead, it generates enough genetic material from whatever genomes are present to support sequencing. That choice matters, because it means the method is not limited to a preselected panel of species—it can in principle reveal anything in the sample, including organisms nobody was actively looking for.

The amplified DNA is then loaded onto a portable nanopore sequencing device. Nanopore sequencing works by threading individual DNA molecules through nanoscale pores and reading their sequence as they pass through, and unlike platforms that require a completed run before results can be assessed, it generates data in real time as the run progresses. The resulting sequences are matched against a custom-built reference database containing genetic information from a wide range of microorganisms, including the fungal and bacterial pathogens most commonly associated with bloodstream infections. This combination of real-time sequencing and a curated database is what allows the workflow to deliver an answer within hours rather than days.

In tests using 48 clinical blood culture samples representing eight fungal species, the workflow achieved species-level identification within approximately seven hours. The method successfully identified a range of clinically important pathogens, including Candida albicans, Nakaseomyces glabratus, Candida parapsilosis, Candida tropicalis, and Cryptococcus neoformans. Perhaps most strikingly, it detected mixed infections in some samples—involving either two fungal species or both fungi and bacteria—a scenario that conventional culture-based workflows often handle poorly, since one organism can outgrow and mask another during incubation.

Because the workflow captures the full genome of the pathogen rather than a single marker gene, it offers a bonus beyond speed: the ability to detect genetic variants in genes associated with drug resistance. That capability could eventually inform not just which species is infecting a patient, but which drugs that particular strain is likely to respond to, bringing precision medicine to an area of infectious disease where treatment decisions have long been made under uncertainty. “Our method may enable clinicians to initiate appropriate antifungal treatment earlier, potentially improving outcomes for patients with life-threatening fungal bloodstream infections,” Professor Takahashi noted. His motivation, he explained, grew from a background in sequence analysis and genomics and a desire to apply modern genomic technologies to the clinical challenge of fungal infections.

The researchers are careful to note that hurdles remain before the approach reaches routine clinical use. Further work is needed to determine the optimal timing for collecting samples during the incubation period, and detection still falters when heavy bacterial growth masks fungal signals in mixed infections. Additional validation will be required to confirm performance across broader patient populations and diverse pathogen profiles. Even so, the study demonstrates a credible path toward rapid diagnostic procedures for life-threatening fungal infections—procedures that could shorten the dangerous gap between infection and effective therapy, reduce the indiscriminate use of broad-spectrum antifungals, and ultimately improve survival for the hospitalized patients most at risk.

Subject of Research: Rapid nanopore whole-genome sequencing for species-level diagnosis of fungal bloodstream infections

Article Title: Faster diagnosis for fungal bloodstream infections

Article References: Faster diagnosis for fungal bloodstream infections. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: fungal bloodstream infections, Candida, nanopore sequencing, blood culture, host DNA depletion, whole-genome amplification, antifungal resistance, rapid diagnostics, Chiba University, Microbiology Spectrum, clinical microbiology, drug resistance genes

The clinical stakes could hardly be higher. Candida species are among the most common opportunistic fungal pathogens in humans, causing everything from superficial mucocutaneous irritation to invasive systemic disease associated with significant morbidity and death. Vulvovaginal candidiasis alone affects 70 to 75 percent of women at least once in their lifetime, and 40 to 50 percent suffer recurrent episodes that erode quality of life and resist repeated treatment. Current therapy rests on three drug classes: azoles such as fluconazole, polyenes such as amphotericin B and nystatin, and the newer echinocandins. All carry drawbacks, including hepatotoxicity, drug-drug interactions, local irritation, and contraindications in pregnancy, and the global rise of antifungal resistance, particularly among Candida albicans, Candida glabrata, and Candida krusei, is steadily eroding their long-term effectiveness.

Against that backdrop, the review’s quantitative findings are remarkable. Reported minimum inhibitory concentrations for propolis extracts ranged from as low as 0.2 micrograms per milliliter for certain Brazilian propolis types to as high as 10,000 micrograms per milliliter for samples from Brunei, a spread that maps directly onto the chemical richness of each regional source. Brazilian red and green propolis, Nigerian red propolis rich in the isoflavanol DDI, and Moroccan propolis containing epicatechin and apigenin consistently showed the lowest MIC values, in some cases matching or exceeding fluconazole itself. Mexican stingless bee propolis recorded MICs of just 1.62 to 2.50 micrograms per milliliter, roughly 30 percent lower than honeybee propolis from the same assays. By contrast, Bruneian samples showed weak activity, likely because they lack the key bioactive constituents.

What makes propolis pharmacologically interesting is not a single magic-bullet molecule but its multi-target mode of action. The most frequently observed mechanism is disruption of the fungal cell membrane and wall. Amphipathic phenolic compounds such as p-coumaric acid, caffeic acid phenethyl ester, pinocembrin, quercetin, and benzophenones integrate into fungal lipid bilayers, forming pores, destabilizing membrane potential, and causing cytoplasmic leakage. Electron microscopy has confirmed cell shrinkage, wall rupture, and loss of membrane integrity in C. albicans and C. krusei. Molecular docking studies add a second layer: propolis constituents appear to inhibit lanosterol 14-alpha-demethylase, the ergosterol-biosynthesis enzyme that azoles target, and dihydrofolate reductase, interfering with folate metabolism and fungal viability.

Equally important is propolis’s activity against biofilms, the structured fungal communities that coat dentures, catheters, titanium implants, and mucosal surfaces and that tolerate antifungal drug concentrations hundreds of times higher than planktonic cells can survive. Studies compiled in the review show propolis disrupting both developing and mature biofilms by impairing cell adhesion, degrading the extracellular matrix of polysaccharides, proteins, and extracellular DNA, and suppressing metabolic activity. Treatment reduced viable cells in mature C. albicans biofilms by up to 4 log colony-forming units. Ecuadorian stingless bee propolis cut biofilm formation by 63 to 80 percent, while Brazilian red propolis inhibited biofilm metabolic activity at concentrations as low as 15.6 micrograms per milliliter.

Propolis also attacks Candida virulence at the genetic and morphological level. Iraqi propolis downregulated the expression of ECE1, SAP5, and ALS3, genes governing hyphal extension, protease secretion, and adhesion, thereby blunting the pathogen’s ability to invade tissue. Other studies showed that propolis blocks the yeast-to-hyphae transition, the morphological switch central to tissue invasion, by interfering with cAMP-PKA signaling and inducing oxidative stress that triggers mitochondrial dysfunction and apoptotic cell death. Because these mechanisms strike simultaneously at structure, morphogenesis, and virulence regulation, the review argues, the probability of Candida developing compensatory resistance is substantially reduced compared with single-target drugs.

Perhaps the most clinically provocative finding concerns synergy with existing antifungals. When propolis extracts, or isolated constituents such as caffeic acid phenethyl ester and quercetin, were combined with fluconazole, nystatin, or itraconazole, minimum inhibitory concentrations fell by up to 64-fold, and azole susceptibility was restored in resistant strains, apparently through increased membrane permeability and suppression of efflux pump function. In fluconazole-resistant C. glabrata and C. krusei, propolis bypasses the classic resistance mechanisms of ERG11 mutation and efflux overexpression entirely, and in specific assays achieved complete eradication of C. glabrata at zero colony-forming units per milliliter, outperforming standard fluconazole. This positions propolis as an adjuvant capable of lowering drug doses and forestalling the emergence of resistance.

Human and animal evidence, though still limited, reinforces the laboratory picture. In an Indonesian clinical study, propolis wax ovules from the stingless bee Tetragonula sp., applied once daily for seven days, achieved remission rates in vulvovaginal candidiasis comparable to nystatin, with no additional adverse effects. Bulgarian propolis added to toothpaste eradicated C. albicans in adolescents with gingivitis, and in pediatric oral candidiasis propolis produced a mean inhibition zone of 9.5 millimeters with good tolerability. In murine models of vaginal candidiasis, thermoresponsive mucoadhesive propolis platforms and nano-encapsulated green propolis eliminated C. albicans without visible tissue toxicity, while photodynamic therapy mediated by the red propolis compound gutiferone significantly lowered fungal burden in models of denture stomatitis.

Formulation science emerges as a decisive variable. Nanoemulsions improved the tissue penetration and bioavailability of lipophilic benzophenones, producing more than 78 percent fungal cell damage in mucocutaneous tissue, and natural rubber latex membranes loaded with propolis released active compounds in a sustained, non-toxic manner suitable for wound healing. The review also highlights novel delivery chemistry, including pH-aligned natural deep eutectic solvents, or NaDES, and microcapsules, as the frontier beyond traditional ethanolic extraction. Combining propolis with chelating agents such as EDTA or phytic acid further weakens fungal membrane ionic stability, amplifying cellular damage. Geographic origin, botanical source, and extraction method all shape potency, and advances in high-resolution mass spectrometry have now identified stable marker compounds such as Sulawesin A and B in Indonesian propolis, opening a path toward the standardization that pharmaceutical development demands.

The authors are careful to temper enthusiasm with candor. Chemical variability across regions remains a major obstacle to universal dose standardization, laboratory inhibition halos and MIC values do not always translate into clinical outcomes given the complexity of the vaginal environment and the phenomenon of trailing growth in some Candida species, and large-scale randomized controlled trials are still scarce relative to laboratory studies. Their conclusion is measured but firm: propolis is best positioned today as a complementary therapeutic agent and a bioactive ingredient in innovative drug delivery systems rather than a wholesale replacement for standard antifungals. Yet by bridging molecular mechanism and clinical remission, and by mapping Indonesian biodiversity markers against the rising global tide of antifungal resistance, the review makes the case that the hive’s ancient resin deserves a serious place in modern pharmacology.

Subject of Research: Antifungal activity of propolis against Candida species, including resistant strains

Article Title: Antifungal activity of propolis against Candida spp.

Article References: Rohmatin, E., Sahlan, M., & Hermansyah, H. (2026). Antifungal activity of propolis against Candida spp.. New Microbes and New Infections, 74, Article 101856. https://doi.org/10.1016/j.nmni.2026.101856

Image Credits: AI Generated

DOI: 10.1016/j.nmni.2026.101856

Keywords: propolis, Candida, antifungal resistance, vulvovaginal candidiasis, biofilms, flavonoids, fluconazole, natural products, honeybees, systematic review, Candida albicans, drug delivery

The team was interested in two particular lichen secondary metabolites: usnic acid, a yellow pigment famous among natural products chemists, and atranorin, a depside compound common in many lichen thalli. Both have documented biological activities, but the researchers set out with a more nuanced question. If individual compounds can kill bacteria on their own, does the full chemical cocktail found in a crude lichen extract do the job even better? The answer from their experiments appears to be a cautious yes, with evidence suggesting that mixtures of metabolites may act synergistically rather than as isolated single agents.

To get a reliable picture of what was inside each extract, the scientists used high-performance liquid chromatography coupled with a diode array detector, an analytical technique that separates complex mixtures and identifies compounds based on how they absorb ultraviolet light. After extracting the lichen material with a one-to-one mixture of methanol and acetone, they quantified usnic acid and atranorin across all eight species. The concentrations ranged from a modest 0.024 percent up to 1.2 percent for usnic acid, and from 0.018 to 0.46 percent for atranorin. These numbers matter because they allow direct comparison between the chemical composition of each species and its measured biological effect, transforming what could have been a simple screening exercise into a structured structure-activity investigation.

The antimicrobial results are where the study becomes genuinely striking. The researchers tested their extracts against four strains of Staphylococcus aureus, the notorious bacterium responsible for everything from skin infections to life-threatening sepsis and a World Health Organization priority pathogen. Using broth microdilution assays to determine the minimum inhibitory concentration, they found that all eight lichen extracts suppressed bacterial growth at concentrations between 0.1 and 0.35 milligrams per milliliter. That places the crude extracts in the same potency range as gentamicin, a standard clinical antibiotic tested at 0.1 milligrams per milliliter in the same assays. Pure usnic acid was even stronger at 0.02 milligrams per milliliter, but the fact that unfractionated extracts approached clinical-antibiotic territory is remarkable for unmodified natural material.

Crucially, the team went beyond simply asking whether the extracts stopped growth. They determined the minimum bactericidal concentration for each extract, the dose at which bacteria are actually killed rather than merely inhibited. When the ratio of the bactericidal concentration to the inhibitory concentration falls below four, microbiologists classify a substance as genuinely bactericidal. Every extract in the study met that criterion against the staphylococcal strains, meaning these lichen compounds do not just hold bacteria in check but destroy them. The same logic applied to the antifungal experiments, where minimum fungicidal concentration to minimum inhibitory concentration ratios also fell below four against the tested Candida strains.

That antifungal activity, while real, was more modest. Extracts inhibited Candida growth at concentrations between 0.4 and 1.0 milligrams per milliliter, a range the authors characterize as moderate. Candida species are among the most common fungal pathogens of humans, and rising resistance to existing antifungal drugs has made the search for new chemical scaffolds increasingly urgent. While a lichen extract would need considerable development before it could inform any clinical antifungal, the finding that these same extracts carry fungicidal activity alongside potent antibacterial effects makes them chemically richer candidates for follow-up work than many single-purpose natural products.

The study also examined antioxidant capacity, another dimension of lichen chemistry that has attracted attention for its possible health relevance. Using three complementary assays, the researchers measured the ability of the extracts to neutralize synthetic radicals and reduce iron. In the DPPH radical scavenging assay, effective concentrations fell between 1364 and 2461 micrograms per milliliter. The ABTS decolorization assay yielded values from 11.5 to 15.9 milligrams of Trolox equivalents per gram, while the ferric reducing antioxidant power assay produced readings between 169 and 719.79 micromoles of iron equivalents per gram. Total phenolic content, measured with the Folin-Ciocalteu method, ranged from 11.34 to 332.15 micrograms of gallic acid equivalents per gram, a wide spread that highlights just how chemically different these eight co-occurring species can be.

Among the species tested, one stood out in the antioxidant profiling: the extract of Alectoria ochroleuca showed the second-highest total phenolic content and a moderate antioxidant performance across the assays. Phenolic compounds are well-established antioxidants because their molecular structures can donate electrons or hydrogen atoms to neutralize reactive oxygen species, the unstable molecules implicated in cellular damage, aging, and numerous diseases. In lichens, which endure intense ultraviolet radiation and desiccation on exposed mountain surfaces, an arsenal of protective phenolics makes evolutionary sense. Atranorin and usnic acid themselves contribute to this chemical sunscreen and defense system, which is precisely why lichens have become such attractive targets for pharmacological screening.

The authors are careful about interpretation, and appropriately so. Because pure usnic acid outperformed the crude extracts against Staphylococcus aureus, and because the biological effects did not map neatly onto the concentrations of any single measured compound, the data point toward synergy among metabolites. In natural products research, synergy is both an opportunity and a complication. It can mean that combinations of molecules achieve effects no individual component could, potentially through multiple mechanisms of attack that also make resistance harder to develop. But it also means that isolating a single magic molecule may never fully reproduce the activity of the whole extract, complicating standardization and drug development. The study’s conclusion emphasizes that future work isolating individual metabolites and evaluating their bioactivity in vivo will be needed to confirm the pharmacological relevance of these extracts.

What makes this research resonate beyond the laboratory is its setting. Lichens are among the hardiest organisms on the planet, thriving on bare rock, tree bark, and harsh Andean slopes where almost nothing else grows, and their chemical inventories remain astonishingly underexplored. Studies like this one, combining rigorous chromatographic quantification with standardized susceptibility testing and antioxidant assays, provide exactly the kind of reproducible baseline data needed to turn folklore about healing lichens into testable pharmacology. With antibiotic resistance climbing worldwide and the pipeline of new drugs running thin, the humble organisms carpeting a Peruvian mountainside may hold molecular lessons that modern medicine has barely begun to read. The next chapter will depend on whether the synergistic activity seen in these crude extracts survives the journey from the extraction flask through animal studies and, eventually, toward the clinic.

Subject of Research: Antimicrobial and antioxidant activities of eight Peruvian lichen species analyzed by HPLC-DAD quantification of usnic acid and atranorin.

Article Title: HPLC-DAD quantification of usnic acid and atranorin and evaluation of antibacterial and antifungal activities in eight peruvian lichens

Article References: Carrasco, F., Hernández, W., Guerrero, M., Rojas, R., Tamariz-Angeles, C., Olivera-Gonzales, P., Briceño-Luna, V., Solis, E. C., Raposo, C., Rodilla, J. M., & Silva, L. (2026). HPLC-DAD quantification of usnic acid and atranorin and evaluation of antibacterial and antifungal activities in eight peruvian lichens. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05599-6

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05599-6

Keywords: lichens, usnic acid, atranorin, HPLC-DAD, antimicrobial activity, antioxidant, Peru, Staphylococcus aureus, Candida, natural products, secondary metabolites, synergy

Carbon dots have quietly attracted attention over the past decade for their unusual combination of properties. They are photochemically stable, biocompatible, low in toxicity, and fluorescent, which has already made them useful in cellular imaging, biosensing, and drug delivery. But what makes them especially interesting in the antibiofilm arena is their synthetic flexibility. Researchers can choose precursors and synthesis methods that deliberately install specific surface functionalities—amines for a positive charge, carboxylic acids for a negative charge, or hydrophobic domains—each of which governs how the dots interact with the complex architecture of a biofilm and the cells hidden within it. In other words, the recipe determines the weapon.

The review, written by a team led by Hadeer M. Bedair and Tamer M. Samir, categorizes synthesis strategies into top-down and bottom-up approaches, with the latter dominating current research. Hydrothermal, solvothermal, microwave-assisted, pyrolysis, and thermal decomposition methods convert small organic molecules or biomass into nanosized carbon cores through dehydration, polymerization, aromatization, and carbonization. Microwave-assisted synthesis has emerged as a standout because it heats the reaction volumetrically through dielectric heating, shrinking reaction times from hours to minutes while promoting homogeneous nucleation and often improving fluorescence and yield. Still, the method is not without drawbacks: product quality depends heavily on microwave power, reaction time, precursor composition, and solvent properties, and scale-up remains challenging because microwave penetration depth decreases as reaction volume grows—a limitation that pushes researchers toward dedicated laboratory reactors rather than domestic ovens.

When it comes to Gram-positive bacteria, the review finds that cationic design has been the dominant strategy. The cell walls of bacteria such as Staphylococcus aureus carry a net negative charge, courtesy of teichoic acids and phospholipid membranes, so positively charged dots bind electrostatically and tear membranes apart. The comparative data reveal striking differences. Quaternized carbon dots achieved complete prevention of S. aureus biofilm at 1,000 micrograms per milliliter, while polyethyleneimine–citric acid dots required 1,500 micrograms per milliliter. In contrast, spermidine-capped carbon dots achieved 81.34 percent inhibition at just 16 micrograms per milliliter, and guanidinium-based dots reduced methicillin-resistant S. aureus biofilm to near-zero levels at 20 micrograms per milliliter. The guanidinium group, capable of forming bidentate hydrogen bonds with negatively charged cell-surface components in addition to electrostatic attraction, appears to be a particularly potent motif. The message is clear: the molecular architecture of the cationic moiety matters as much as the charge itself.

Beyond brute-force electrostatics, the review highlights increasingly sophisticated smart designs. Folic acid-derived carbon dots exploit folate receptors overexpressed on many bacterial species to target infection sites, disrupting 82 percent of mature S. aureus biofilms at 1,000 micrograms per milliliter. A pH-responsive dissociable nanosystem remains inert during transit but disassembles within the acidic microenvironment of a growing biofilm, releasing both a biocidal cationic polymer and l-lysine-derived dot cores that generate intracellular reactive oxygen species, degrading the extracellular matrix and killing embedded bacteria. Perhaps most striking is a conversion strategy in which the antibiotic gentamicin sulfate was directly calcined into carbon dots, yielding a material that retained the parent drug’s active structure while gaining a positively charged surface and reactive oxygen species generation. The result: more than 99 percent destruction of S. aureus biofilms at just 80 micrograms per milliliter, with low observed drug resistance—a compelling route to repurposing existing antibiotics into multifunctional nanomaterials.

Gram-negative pathogens present a far harder problem. Their outer membrane, an asymmetric bilayer rich in lipopolysaccharide, functions as a formidable permeability barrier that blunts the electrostatic interactions so effective against Gram-positive cells. Nitrogen-doped dots that fully inhibited Bacillus subtilis biofilm at 25 milligrams per milliliter required the same high concentration to inhibit Escherichia coli, a disparity the authors attributed to the thicker lipopolysaccharide layer. Effective concentrations against Gram-negative targets in the reviewed literature span more than four orders of magnitude, from 4 micrograms per milliliter to 25,000. The most potent systems share a common feature: multiple synergistic mechanisms rather than electrostatics alone. A cobalt-nickel ferrite/silica/titania/carbon-dot nanocomposite combining photocatalysis with magnetic properties inhibited 93.92 percent of E. coli biofilm at just 15 micrograms per milliliter. An iron and nitrogen co-doped nanozyme with peroxidase-like activity achieved 73.2 percent inhibition of Hafnia alvei biofilm at 4 micrograms per milliliter by converting hydrogen peroxide into toxic hydroxyl radicals—and, in a practical demonstration, extended the shelf life of salmon by three to six days. Red-emissive dots activated by light achieved 85 percent inhibition of multidrug-resistant Acinetobacter baumannii biofilm at 150 micrograms per milliliter through photodynamic generation of reactive oxygen species, an approach particularly suited to wound and device infections where light can be applied externally.

Fungal biofilms, especially those formed by Candida species, represent a distinct clinical challenge because fungal cells are eukaryotic, making selective toxicity substantially harder to achieve. The review notes that research here remains scarce but promising. Simple dots made from Citrus limetta fruit juice achieved a modest 40 percent reduction of Candida albicans biofilm at 75 micrograms per milliliter, likely through interference with quorum sensing and initial adhesion. More sophisticated designs fared better: guanidine-functionalized red-emissive dots conjugated with amphotericin B significantly reduced C. albicans biofilm at 100 micrograms per milliliter while preserving the integrity of reconstituted human oral epithelial tissue—a crucial demonstration of selective toxicity. The magnetic-photocatalytic nanocomposite inhibited 92.35 percent of Candida tropicalis biofilm at 15 micrograms per milliliter, though its lower activity against C. albicans underscores how sharply antifungal susceptibility varies even within a single genus. In another innovative approach, red-emitting dots embedded in poly-l-lactic acid scaffolds convert near-infrared light into localized heat, achieving 60 percent inhibition of clinical Candida parapsilosis biofilms—a physical mechanism unlikely to induce resistance and readily adaptable to self-sterilizing medical devices.

Mechanistically, the review argues that no single mode of action explains carbon dot antibiofilm activity; rather, the most effective systems combine several. Electrostatic binding initiates contact with anionic bacterial surfaces and matrix components. The ultrasmall size of the dots—typically below ten nanometers—allows them to diffuse through the water channels of the extracellular matrix that exclude most conventional antibiotics, reaching persister cells in the deepest layers. Once internalized, many dots trigger intracellular reactive oxygen species, damaging proteins, lipids, and DNA while simultaneously degrading the matrix polysaccharides and extracellular DNA that hold the biofilm together. Intriguingly, some dots work without killing cells at all. Curcumin-derived dots downregulated adhesion and biofilm maturation genes in Enterococcus faecium, while tinidazole-functionalized dots suppressed fimbriae and protease genes in Porphyromonas gingivalis. Bacteria-derived dots inhibited E. coli biofilm formation without affecting planktonic growth at all, pointing to specific interference with regulatory pathways such as sulfur metabolism or cyclic di-GMP signaling. This disarming strategy, which disrupts the regulatory networks governing biofilm formation rather than the cells themselves, may exert less selective pressure for resistance—one of the most tantalizing implications of the entire field.

The authors are candid about the hurdles between laboratory promise and clinical reality. Effective concentrations vary enormously across studies, partly because testing protocols are not standardized, making direct comparisons difficult. The molecular events governing how dots traverse the Gram-negative outer membrane, and how they achieve selective toxicity against microbes without harming mammalian cells, remain poorly understood. Almost all published results come from in vitro experiments; long-term biocompatibility, biodistribution, pharmacokinetics, immunogenicity, and environmental safety in living organisms have barely been examined. Large-scale production, batch-to-batch consistency, storage stability, and regulatory approval remain unsolved. The review calls for standardized synthesis and characterization protocols, systematic structure–activity studies, testing against clinically relevant multispecies biofilms and drug-resistant isolates in realistic infection models, and eventually rigorous preclinical and clinical trials. If those challenges are met—potentially aided by artificial intelligence-assisted nanomaterial design and green synthesis—the authors believe carbon quantum dots could evolve from experimental curiosities into safe, effective platforms for the prevention, diagnosis, and treatment of biofilm-associated infections, offering a genuinely new weapon against one of medicine’s most persistent enemies.

Subject of Research: The antibiofilm activity of carbon quantum dots against bacteria and fungi

Article Title: Insights Into the Antibiofilm Activity of Carbon Quantum Dots Against a Panel of Different Microorganisms: A Review

Article References: Bedair, H. M., Hamed, M., Shoun, A. A., Mansour, F. R., Obaydo, R. H., & Samir, T. M. (2026). Insights Into the Antibiofilm Activity of Carbon Quantum Dots Against a Panel of Different Microorganisms: A Review. MicrobiologyOpen, 15(5), Article e70411. https://doi.org/10.1002/mbo3.70411

Image Credits: AI Generated

DOI: 10.1002/mbo3.70411

Keywords: carbon quantum dots, biofilms, antimicrobial resistance, nanomaterials, MRSA, reactive oxygen species, quorum sensing, Gram-negative bacteria, Candida, nanotechnology, antibiofilm therapy, photodynamic therapy

The research, conducted by a team at Semmelweis University in Budapest along with collaborators in Romania and Hungary, took the form of a systematic review and meta-analysis published in the journal Gut Pathogens. Rather than relying on any single centre’s experience, the investigators systematically searched the medical literature for studies reporting on the microbiological profile of patients undergoing endoscopic or percutaneous drainage for infected walled-off necrosis or pancreatic pseudocysts. These two types of pancreatic fluid collections represent distinct pathological entities. Walled-off necrosis arises when areas of dead pancreatic or surrounding tissue become encapsulated by a wall of inflammatory tissue, typically four or more weeks after the onset of necrotising pancreatitis. Pancreatic pseudocysts, by contrast, are fluid-filled cavities bounded by fibrous tissue that lack the solid necrotic component. Both can become infected, and both are increasingly managed through minimally invasive drainage rather than open surgery, making the organisms they harbour directly relevant to treatment decisions.

After screening the available literature according to a protocol registered in advance on the PROSPERO international prospective register of systematic reviews, the team identified thirty-one eligible studies encompassing one thousand two hundred and eighty-six patients with culture-positive infections of pancreatic fluid collections. The pooled analysis revealed a microbial ecosystem dominated by organisms that originate in the gastrointestinal tract, which makes anatomical sense given that the pancreas lies adjacent to the duodenum and that pancreatic fluid collections frequently communicate with the gut either through the pancreatic duct or through erosion into adjacent bowel. Escherichia coli emerged as the single most prevalent bacterium in infected walled-off necrosis, detected in twenty-one percent of cases with a ninety-five percent confidence interval spanning thirteen to thirty-one percent. Enterococcus species followed closely at twenty percent, with a wider confidence interval of twelve to thirty-three percent reflecting the heterogeneity of the underlying studies.

Perhaps the most striking finding was the prominence of Candida species, detected in twenty percent of infected walled-off necrosis cases with a confidence interval of eleven to thirty-three percent. The presence of this fungal genus at rates comparable to the leading bacterial pathogens challenges the traditional assumption that bacterial organisms alone drive the majority of these infections. Candida is a normal inhabitant of the gastrointestinal tract, and its appearance in pancreatic collections likely reflects translocation from the gut across compromised mucosal barriers. The finding has important therapeutic implications because standard empiric antibiotic regimens for intra-abdominal infections typically do not cover fungi, meaning that clinicians who rely on broad-spectrum antibacterial agents alone may miss a substantial proportion of causative organisms.

The analysis also quantified the burden of antimicrobial resistance in these collections, finding that multidrug-resistant organisms were present with a pooled prevalence of twenty-four percent among infected patients, with a confidence interval stretching from ten to fifty percent. This wide range reflects significant variability across the included studies, likely driven by differences in local antibiotic prescribing practices, infection control infrastructure, and patient populations. Nevertheless, the central estimate is alarming because it means that approximately one in four patients with an infected pancreatic fluid collection harbours organisms resistant to multiple first-line antimicrobial agents. The authors noted that the spectrum of resistance includes extended-spectrum beta-lactamase producing Enterobacteriaceae, methicillin-resistant Staphylococcus aureus, and vancomycin-resistant Enterococcus, each of which demands specific therapeutic agents that may not be part of standard empiric protocols.

One of the most clinically valuable contributions of the study lies in its regional stratification, which exposed dramatic geographical variation in pathogenic distribution. In European patients, Candida species predominated at thirty-eight percent with a confidence interval of twenty-three to fifty-six percent, followed by Enterococcus species at thirty-five percent. In Asian populations, the picture shifted markedly, with Escherichia coli leading at twenty-nine percent and Klebsiella species rising to twenty-seven percent. This east-west divide has tangible implications for how empiric antibiotic therapy should be selected. A clinician in Budapest or Bucharest facing a patient with suspected infected pancreatic necrosis might reasonably weight antifungal and anti-enterococcal coverage more heavily, while a counterpart in Seoul or Mumbai would need to ensure robust coverage against gram-negative organisms including Klebsiella, which in many Asian centres carries elevated rates of carbapenem resistance.

When the researchers turned their attention specifically to infected pancreatic pseudocysts rather than walled-off necrosis, they found a somewhat different hierarchy. Escherichia coli was again the leading pathogen at twenty-nine percent, though with a very wide confidence interval of eight to sixty-five percent that underscores the smaller number of studies and patients available for this subgroup. Staphylococcus species followed at twenty-five percent, and Klebsiella species came in at eighteen percent. The broader confidence intervals for pseudocyst-associated infections reflect the relative rarity of infected pseudocysts compared with infected necrosis, since pseudocysts are less likely to harbour solid necrotic debris that serves as a nutrient-rich medium for bacterial proliferation. Nevertheless, the finding that Staphylococcus species rank second in pseudocyst infections is noteworthy because it suggests a possible role for skin flora or healthcare-associated contamination in these collections, particularly when interventions such as fine-needle aspiration or drainage have been performed.

The technical challenges of obtaining reliable microbiological data from pancreatic fluid collections deserve careful consideration. Culture results can be influenced by the sampling method employed, whether by endoscopic ultrasound-guided fine-needle aspiration, direct puncture during drainage, or percutaneous catheter placement. Prior antibiotic exposure, which is nearly universal in these patients by the time drainage is attempted, can suppress the growth of susceptible organisms and lead to false-negative cultures or an overrepresentation of resistant species. The heterogeneity of sampling modalities across the thirty-one included studies represents a limitation that the authors acknowledged, noting that marked variation across regions and sampling techniques contributed to the wide confidence intervals observed for many organisms. The researchers also pointed out that the retrospective and observational nature of most included studies means that temporal trends in resistance patterns could not be reliably assessed, and that the findings warrant further prospective evaluation.

The clinical implications of this work extend beyond the choice of individual antibiotics. The authors argue that recognition of regional pathogenic distribution should inform antimicrobial stewardship programmes, which aim to optimise antibiotic use to preserve efficacy and limit the emergence of resistance. In the context of infected pancreatic fluid collections, stewardship involves a delicate balance. Empiric coverage must be broad enough to address the likely pathogens, including consideration of fungal coverage in European settings, yet targeted de-escalation based on culture results is essential to avoid selecting for multidrug-resistant organisms. The finding that nearly a quarter of infections involve multidrug-resistant organisms adds urgency to calls for rapid diagnostic methods that can identify pathogens and their resistance profiles within hours rather than days, allowing clinicians to narrow therapy sooner and spare patients the toxicities and costs of unnecessarily broad regimens.

This study represents a significant step forward in understanding the microbiological underpinnings of one of the most feared complications of acute pancreatitis. By synthesising data from thirty-one studies and over twelve hundred patients across multiple continents, it provides clinicians with evidence-based benchmarks against which to judge their local microbiology results and to calibrate empiric therapy. The dominance of enteric organisms confirms that the gut serves as the primary reservoir for infection in these collections, while the unexpected prominence of Candida species and the substantial burden of antimicrobial resistance highlight gaps in current treatment paradigms. As the authors conclude, a diverse microbial profile with enteric organisms, fungal pathogens, and significant heterogeneity across regions characterises infected pancreatic fluid collections, and integrating this knowledge into clinical practice may ultimately translate into better outcomes for patients facing these life-threatening complications.

Subject of Research: Microbiological profile of infected walled-off pancreatic necrosis and pseudocysts

Article Title: The microbiological landscape of infected walled-off necrosis and pancreatic pseudocysts: a systematic review and meta-analysis

Article References: Brand, T., Marchis, A., Grigorovici, R., Aviv, K., Tóth, R., Bunduc, S., Mihály, E., Obeidat, M., Erőss, B., Hegyi, P., & Hegyi, P. J. (2026). The microbiological landscape of infected walled-off necrosis and pancreatic pseudocysts: a systematic review and meta-analysis. Gut Pathogens. https://doi.org/10.1186/s13099-026-00883-9

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00883-9

Keywords: acute pancreatitis, walled-off necrosis, pancreatic pseudocyst, pancreatic fluid collections, Escherichia coli, Enterococcus, Candida, multidrug resistance, antimicrobial stewardship, endoscopic drainage, meta-analysis, microbiology